Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OXN PR vs Oxy PR for Opioid-Induced Constipation
NCT01014559Phase 3Terminated
- Sponsor
- Mundipharma
- Start
- Feb 2010
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of oxycodone + naloxone in opioid-induced constipation (OIC) (2 arms), sponsored by Mundipharma. Primary endpoint: Bowel Function Index at 28 days. Started Feb 2010; status: terminated.
02
Drugs
oxycodone + naloxone
03
Conditions
opioid-induced constipation (OIC)
Beyond the preview
Go deeper on NCT01014559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01014559.